Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 264

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 264
---

of developing CogniMIR. To date, DiamiR has primarily earned revenue from grants and have not generated any product revenue
other than revenues from research testing services for third parties and other revenue generated for performing laboratory services DiamiR
previously provided to Interpace Biosciences, Inc. (“Interpace”). DiamiR’s ability to generate product revenue, which
it does not expect to occur until at least second half 2025, if ever, will depend heavily on DiamiR’s ability to comply with
regulatory requirements for, and to commercialize successfully, CogniMIR and other tests in development.

Total Operating Expense

Total operating costs and expenses
consisted primarily of analyzing samples and clinical data associated with revenues from research testing services performed, patent costs
and general and administrative costs.

Results of Operations

Results of Operations for the three months ended August 31, 2025 are incorporated by reference to the Current Report on Form 6-K that was filed on October 15, 2025.

For the Years Ended May 31, 2025 and 2024

| Statement of Operations Data:      |     | For the Years Ended 
 May 31,             
 2025                |           |   |     | 2024 |           |   |     | Change |          |   |
|:-----------------------------------|:----|:--------------------|----------:|:--|:----|:-----|----------:|:--|:----|:-------|---------:|:--|
| Grant revenue                      |     | $                   |   531,729 |   |     | $    | 1,319,531 |   |     | $      | (787,802 | ) |
| Other revenue                      |     |                     |   100,000 |   |     |      |         — |   |     |        |  100,000 |   |
| Total revenue                      |     |                     |   631,729 |   |     |      | 1,319,531 |   |     |        | (687,802 | ) |
| Operating costs and expenses       |     |                     |           |   |     |      |           |   |     |        |          |   |
| Research and development           |     |                     |   650,591 |   |     |      | 1,156,860 |   |     |        | (506,269 | )